For the third quarter of the fiscal year ending December 2026, consolidated revenue was 29,731 million yen, a significant year-over-year increase. Operating income turned positive to 73 million yen. With the acquisition of Ayumi Pharmaceutical Holdings as a wholly owned subsidiary and business expansion of Gyre Pharmaceuticals, the Pharmaceuticals segment achieved higher revenue and profit, while the Medical Devices segment saw declines in both revenue and profit. There is no revision to the full-year outlook.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2160","jir_company_name":"GNI Group Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-13","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/2160-20261113-01.pdf","jir_short_summary":"For the third quarter of the fiscal year ending December 2026, consolidated revenue was 29,731 million yen, a significant year-over-year increase. Operating income turned positive to 73 million yen. With the acquisition of Ayumi Pharmaceutical Holdings as a wholly owned subsidiary and business expansion of Gyre Pharmaceuticals, the Pharmaceuticals segment achieved higher revenue and profit, while the Medical Devices segment saw declines in both revenue and profit. There is no revision to the full-year outlook.","jir_summary":"### Overview of Results\nIn this quarter, changes in the consolidation scope, including the acquisition of Ayumi Pharmaceutical Holdings as a wholly owned subsidiary, led to a substantial increase in revenue. The Pharmaceuticals business saw revenue growth driven by expanded sales of core products such as Kanonal and osteoporosis treatments, and steady performance of the IPF drug Isurui in the Chinese market. Progress was also reported in development and regulatory review for new drug candidates including F351. The Medical Devices business experienced revenue declines due to the impact of Medicare system revisions in the United States. Overall, the Company maintained operating profitability.\n\n### Outlook and Impact for Investors\nFor the second half, the Company will reflect consolidated results including Ayumi Pharmaceutical Holdings while increasing flexibility in development investments. Acceptance of the NDA for F351 in China and advancement of priority review, along with accelerated global expansion, are expected to be key drivers of revenue growth. While increased R&D expenses will pressure short-term earnings, they are positioned as mid- to long-term growth drivers.","jir_financial_highlights":"Revenue: 29,731 million yen (YoY +53.6%)\nOperating Income: 73 million yen (YoY -)\nQuarterly Profit (Net Income Attributable to Owners of Parent): -4,038 million yen (YoY -)\nTotal Assets: 204,199 million yen (vs. previous consolidated fiscal year-end +143.7%)\nTotal Liabilities: 113,954 million yen (vs. previous consolidated fiscal year-end +256.7%)","jir_category":"","jir_hashtags":"#GNIGroup, #Earnings, #Pharmaceuticals, #MedTech, #SubsidiaryAcquisition","jir_key_figures":"Revenue: 29,731 million yen (YoY +53.6%)\nSegment Profit (Pharmaceuticals): 3,256 million yen (increase YoY)\nTotal Assets: 204,199 million yen, Total Liabilities: 113,954 million yen, Total Equity: 90,245 million yen","jir_meta_title":"GNI Group Ltd. Third Quarter Financial Summary for Fiscal Year Ending December 2026 | Revenue Growth and Increased R&D Investment","jir_meta_description":"Summary of GNI Group Ltd.'s third quarter results for the fiscal year ending December 2026. Revenue was 29,731 million yen, with notable growth and profit contribution from the Pharmaceuticals segment, while Medical Devices declined. The consolidation of Ayumi Pharmaceutical Holdings impacted results. Key points on development progress and the full-year outlook are provided.","jir_og_title":"GNI Group Ltd. Announces FY2026 Third Quarter Financial Summary","jir_og_description":"Key points from the FY2026 third quarter financial summary: significant revenue and profit growth in the Pharmaceuticals segment, consolidation effects from Ayumi Pharmaceutical Holdings, and the Company's approach to development investment.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025Q3\\\",\\\"2026Q3\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[19357,29731]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025Q3\\\",\\\"2026Q3\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[-497,73]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Revenue Breakdown\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Pharmaceuticals\\\",\\\"Medical Devices\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[252326,4404]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Profit Analysis\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Pharmaceuticals\\\",\\\"Medical Devices\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Segment Profit\\\",\\\"data\\\":[3256,-3182]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"table\", \"jir_chart_title\": \"Full-Year Forecast vs. Actual Comparison\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"table\\\",\\\"data\\\":{}}\"}]","ir_related_company":9370,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-153252","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n